cefazolin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 530 25953-19-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefazolin
  • cefazolin sodium
  • cefamezin
  • cefaprim
  • cefazoline
  • cephamezine
  • cephazolin
  • cephazoline
  • cefazolin sodium salt
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
  • Molecular weight: 454.50
  • Formula: C14H14N8O4S3
  • CLOGP: -0.64
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 2
  • TPSA: 156.09
  • ALOGS: -2.97
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 33 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.75 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.89 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 4, 1973 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 434.83 13.36 176 14100 19979 50570869
Anaphylactic reaction 218.04 13.36 154 14122 53901 50536947
Arthrodesis 155.65 13.36 48 14228 2437 50588411
Hypotension 152.99 13.36 253 14023 235216 50355632
Postoperative wound infection 119.95 13.36 55 14221 8420 50582428
Acute generalised exanthematous pustulosis 107.98 13.36 52 14224 8886 50581962
Fatigue 82.60 13.36 49 14227 707552 49883296
Bronchospasm 73.30 13.36 48 14228 14806 50576042
Exposure during pregnancy 72.97 13.36 126 14150 120889 50469959
Drug hypersensitivity 63.93 13.36 185 14091 250825 50340023
Vitamin K deficiency 62.50 13.36 16 14260 407 50590441
Erythema 61.79 13.36 131 14145 146283 50444565
Urticaria 60.65 13.36 121 14155 129440 50461408
Shoulder arthroplasty 60.43 13.36 26 14250 3422 50587426
Amniotic cavity infection 58.46 13.36 19 14257 1144 50589704
Limb operation 57.75 13.36 25 14251 3339 50587509
Type I hypersensitivity 55.41 13.36 22 14254 2363 50588485
Cardiac arrest 52.89 13.36 89 14187 83562 50507286
Premature baby 51.18 13.36 42 14234 18295 50572553
Tachycardia 50.10 13.36 96 14180 99667 50491181
Renal failure 49.18 13.36 99 14177 106534 50484314
Drug-induced liver injury 44.64 13.36 47 14229 28048 50562800
Anaesthetic complication 43.86 13.36 17 14259 1713 50589135
Recurrence of neuromuscular blockade 42.65 13.36 9 14267 94 50590754
Renal injury 40.47 13.36 27 14249 8584 50582264
Kounis syndrome 38.74 13.36 14 14262 1161 50589687
Blood pressure decreased 38.72 13.36 62 14214 55847 50535001
Hypoprothrombinaemia 38.60 13.36 10 14266 267 50590581
Toxic epidermal necrolysis 38.60 13.36 38 14238 20954 50569894
Vascular purpura 38.30 13.36 14 14262 1200 50589648
Rash 38.27 13.36 232 14044 437239 50153609
Alopecia 36.23 13.36 12 14264 245035 50345813
Fear 35.81 13.36 31 14245 14518 50576330
Acute hepatic failure 35.78 13.36 32 14244 15645 50575203
Anhedonia 35.72 13.36 26 14250 9498 50581350
Drug intolerance 35.57 13.36 9 14267 219095 50371753
Purpura senile 32.20 13.36 10 14266 519 50590329
Tarsal tunnel syndrome 32.02 13.36 10 14266 529 50590319
Unevaluable event 31.78 13.36 51 14225 46015 50544833
Product dose omission issue 30.91 13.36 7 14269 183831 50407017
Injury 30.83 13.36 52 14224 48873 50541975
Thrombotic microangiopathy 30.72 13.36 23 14253 8768 50582080
Pseudomembranous colitis 30.03 13.36 15 14261 2770 50588078
Disseminated intravascular coagulation 29.62 13.36 30 14246 17105 50573743
Post procedural complication 29.00 13.36 28 14248 15076 50575772
Headache 28.53 13.36 63 14213 506472 50084376
Multiple organ dysfunction syndrome 28.45 13.36 51 14225 50286 50540562
Death 27.27 13.36 31 14245 325348 50265500
Coagulopathy 26.70 13.36 29 14247 17915 50572933
Hepatic function abnormal 26.50 13.36 39 14237 32642 50558206
Weight increased 26.34 13.36 12 14264 201879 50388969
Foetal anaemia 26.15 13.36 5 14271 30 50590818
Isoimmune haemolytic disease 26.01 13.36 5 14271 31 50590817
Sinusitis 25.82 13.36 8 14268 170550 50420298
Toxic skin eruption 25.74 13.36 23 14253 11228 50579620
Peripheral swelling 25.70 13.36 13 14263 205923 50384925
Hyperthermia malignant 25.10 13.36 9 14267 730 50590118
Premature delivery 24.85 13.36 32 14244 23631 50567217
Systemic lupus erythematosus 24.36 13.36 5 14271 140617 50450231
Post procedural haematoma 24.04 13.36 10 14266 1210 50589638
Pain in extremity 23.96 13.36 25 14251 272840 50318008
Tonic clonic movements 23.91 13.36 10 14266 1227 50589621
Heparin-induced thrombocytopenia 22.50 13.36 14 14262 3951 50586897
Maternal exposure during delivery 22.40 13.36 9 14267 997 50589851
Resorption bone increased 22.35 13.36 9 14267 1002 50589846
Implant site haematoma 22.09 13.36 5 14271 74 50590774
Malaise 22.09 13.36 38 14238 335494 50255354
Pleural effusion 21.58 13.36 61 14215 81393 50509455
Hepatitis cholestatic 21.37 13.36 16 14260 6101 50584747
Haemolytic anaemia 21.27 13.36 19 14257 9273 50581575
Joint swelling 20.94 13.36 23 14253 245263 50345585
Bradycardia 20.88 13.36 52 14224 64374 50526474
Generalised tonic-clonic seizure 20.76 13.36 31 14245 26279 50564569
Acute kidney injury 20.52 13.36 122 14154 227936 50362912
Altered state of consciousness 20.50 13.36 28 14248 21882 50568966
Swelling 20.49 13.36 16 14260 200856 50389992
Vestibular disorder 20.38 13.36 9 14267 1260 50589588
Face oedema 20.12 13.36 25 14251 17814 50573034
Clostridium difficile infection 20.11 13.36 30 14246 25409 50565439
Wound 19.98 13.36 3 14273 105791 50485057
Therapeutic product effect decreased 19.50 13.36 7 14269 136043 50454805
Eosinophilic pneumonia acute 19.46 13.36 6 14270 304 50590544
Shock haemorrhagic 18.97 13.36 17 14259 8327 50582521
Drug reaction with eosinophilia and systemic symptoms 18.96 13.36 31 14245 28393 50562455
Post procedural haemorrhage 18.93 13.36 16 14260 7254 50583594
Laryngeal dyspnoea 18.77 13.36 5 14271 149 50590699
Shock 18.73 13.36 26 14250 20624 50570224
Hypokalaemia 18.71 13.36 61 14215 87931 50502917
Abdominal wound dehiscence 18.52 13.36 5 14271 157 50590691
Pyomyositis 18.40 13.36 6 14270 365 50590483
Spinal cord haematoma 18.23 13.36 5 14271 167 50590681
Oligohydramnios 17.80 13.36 14 14262 5736 50585112
Manipulation 17.75 13.36 4 14272 58 50590790
Hypoventilation 17.72 13.36 12 14264 3909 50586939
Procedural complication 17.71 13.36 13 14263 4810 50586038
Asthenia 17.65 13.36 40 14236 319002 50271846
Oxygen saturation decreased 17.62 13.36 53 14223 73195 50517653
Mycobacterial peritonitis 17.56 13.36 4 14272 61 50590787
Pain 17.56 13.36 94 14182 578809 50012039
Emotional distress 17.44 13.36 30 14246 28633 50562215
Linear IgA disease 17.30 13.36 8 14268 1246 50589602
Injection site pain 17.17 13.36 5 14271 111019 50479829
Clostridium difficile colitis 17.09 13.36 23 14253 17719 50573129
Arthralgia 17.03 13.36 65 14211 438637 50152211
Toxicity to various agents 16.97 13.36 21 14255 212478 50378370
Treatment failure 16.70 13.36 9 14267 137628 50453220
Nasopharyngitis 16.56 13.36 18 14258 192909 50397939
Peritoneal cloudy effluent 16.35 13.36 4 14272 84 50590764
Angioedema 16.18 13.36 34 14242 37642 50553206
Jaundice acholuric 15.97 13.36 4 14272 93 50590755
Keratitis fungal 15.89 13.36 4 14272 95 50590753
Deep vein thrombosis 15.75 13.36 51 14225 73253 50517595
Renal vein thrombosis 15.43 13.36 5 14271 298 50590550
Decorticate posture 15.43 13.36 5 14271 298 50590550
Low birth weight baby 15.43 13.36 13 14263 5868 50584980
Insomnia 15.35 13.36 16 14260 174849 50415999
Irregular breathing 15.23 13.36 5 14271 311 50590537
Alanine aminotransferase increased 15.11 13.36 57 14219 88302 50502546
Cerebral infarction 15.00 13.36 24 14252 21580 50569268
Dizziness 14.98 13.36 49 14227 346320 50244528
Circulatory collapse 14.97 13.36 23 14253 19977 50570871
Foetal growth abnormality 14.94 13.36 3 14273 24 50590824
Arthrofibrosis 14.94 13.36 3 14273 24 50590824
Cholestasis 14.69 13.36 26 14250 25375 50565473
Blood immunoglobulin A decreased 14.53 13.36 5 14271 359 50590489
Serratia test positive 14.43 13.36 3 14273 29 50590819
Septic shock 14.35 13.36 42 14234 57133 50533715
Infusion related reaction 14.35 13.36 16 14260 169541 50421307
Hypoxia 14.24 13.36 39 14237 51084 50539764
Bradycardia foetal 14.18 13.36 5 14271 386 50590462
Multiple lentigines syndrome 14.03 13.36 4 14272 154 50590694
Normal newborn 13.98 13.36 13 14263 6678 50584170
Renal impairment 13.94 13.36 50 14226 75611 50515237
Anaemia 13.91 13.36 120 14156 252336 50338512
Aspartate aminotransferase increased 13.91 13.36 51 14225 77947 50512901
Haemodynamic instability 13.78 13.36 14 14262 8010 50582838
Cholelithiasis 13.75 13.36 32 14244 37941 50552907
Pulseless electrical activity 13.73 13.36 13 14263 6828 50584020
Weight decreased 13.69 13.36 26 14250 221219 50369629
Atelectasis 13.66 13.36 21 14255 18249 50572599
Chest expansion decreased 13.54 13.36 3 14273 40 50590808
Brain oedema 13.41 13.36 17 14259 12353 50578495

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 294.26 14.79 133 12313 13203 29548878
Anaphylactic reaction 220.91 14.79 140 12306 27433 29534648
Hypoprothrombinaemia 148.79 14.79 34 12412 342 29561739
Fear 98.55 14.79 57 12389 9447 29552634
Kounis syndrome 88.09 14.79 32 12414 1797 29560284
Renal injury 77.13 14.79 50 12396 10152 29551929
Anhedonia 74.16 14.79 43 12403 7157 29554924
Injury 72.97 14.79 62 12384 18984 29543097
Hypotension 69.53 14.79 209 12237 194145 29367936
Acute generalised exanthematous pustulosis 67.40 14.79 37 12409 5546 29556535
Drug reaction with eosinophilia and systemic symptoms 66.66 14.79 70 12376 27922 29534159
Emotional distress 63.23 14.79 50 12396 13845 29548236
Fatigue 54.66 14.79 33 12413 316788 29245293
Vitamin K deficiency 54.42 14.79 14 12432 239 29561842
Hypovitaminosis 53.84 14.79 16 12430 474 29561607
Urticaria 49.26 14.79 85 12361 54575 29507506
Unevaluable event 43.37 14.79 58 12388 29793 29532288
Post procedural complication 42.21 14.79 35 12411 10354 29551727
Erythema 40.90 14.79 95 12351 75511 29486570
Vitamin K decreased 38.94 14.79 8 12438 46 29562035
Post procedural hypotension 37.58 14.79 8 12438 56 29562025
Shock 36.45 14.79 45 12401 21359 29540722
Blood pressure decreased 36.18 14.79 67 12379 45410 29516671
Death 35.40 14.79 56 12390 342028 29220053
Bronchospasm 34.19 14.79 30 12416 9579 29552502
Stress 33.13 14.79 43 12403 21447 29540634
Rash 32.70 14.79 162 12284 189657 29372424
Dizziness 32.29 14.79 20 12426 189664 29372417
Adrenal suppression 32.07 14.79 11 12435 521 29561560
Hyperthermia malignant 30.68 14.79 15 12431 1769 29560312
Metabolic acidosis 30.60 14.79 56 12390 37606 29524475
Post procedural haematoma 30.56 14.79 14 12432 1427 29560654
Multiple organ dysfunction syndrome 30.56 14.79 76 12370 63040 29499041
Rash maculo-papular 30.49 14.79 44 12402 24245 29537836
Jaundice cholestatic 30.19 14.79 20 12426 4206 29557875
Renal impairment 29.44 14.79 88 12358 81245 29480836
Gastritis fungal 29.42 14.79 7 12439 85 29561996
Weight decreased 28.44 14.79 14 12432 150891 29411190
Tubulointerstitial nephritis 28.29 14.79 36 12410 17607 29544474
Brain herniation 27.93 14.79 18 12428 3615 29558466
Clostridium difficile colitis 27.86 14.79 31 12415 13181 29548900
Coagulation factor X level decreased 27.20 14.79 5 12441 14 29562067
Ventricular tachycardia 27.04 14.79 40 12406 22534 29539547
Renal failure 26.19 14.79 109 12337 118490 29443591
Pericarditis fungal 25.58 14.79 7 12439 153 29561928
Serotonin syndrome 25.38 14.79 34 12412 17478 29544603
Thymus hypoplasia 25.28 14.79 7 12439 160 29561921
Lymphoid tissue hypoplasia 25.28 14.79 7 12439 160 29561921
Coagulopathy 24.79 14.79 34 12412 17873 29544208
Linear IgA disease 24.21 14.79 12 12434 1457 29560624
Hepatic function abnormal 24.19 14.79 52 12394 39207 29522874
Meningitis fungal 23.69 14.79 6 12440 96 29561985
Pseudomonal sepsis 23.66 14.79 15 12431 2927 29559154
Toxic epidermal necrolysis 22.95 14.79 33 12413 18120 29543961
Conjunctival ulcer 22.38 14.79 5 12441 45 29562036
Anaesthetic complication 22.24 14.79 10 12436 976 29561105
Device related infection 22.12 14.79 30 12416 15606 29546475
Burkholderia test positive 22.12 14.79 10 12436 989 29561092
Type I hypersensitivity 21.44 14.79 10 12436 1062 29561019
Spontaneous haematoma 21.37 14.79 8 12438 489 29561592
Drug-induced liver injury 21.24 14.79 35 12411 21620 29540461
Intrapericardial thrombosis 21.23 14.79 5 12441 58 29562023
Myoclonus 21.09 14.79 27 12419 13282 29548799
Drug hypersensitivity 21.06 14.79 70 12376 68336 29493745
Post embolisation syndrome 20.77 14.79 5 12441 64 29562017
Malaise 20.69 14.79 22 12424 159580 29402501
Factor V inhibition 20.55 14.79 6 12440 167 29561914
Drug eruption 20.53 14.79 30 12416 16711 29545370
Pyrexia 20.23 14.79 197 12249 287425 29274656
Tachycardia 19.59 14.79 71 12375 72339 29489742
Kidney transplant rejection 19.36 14.79 19 12427 6986 29555095
Dysbiosis 19.30 14.79 7 12439 391 29561690
Toxicity to various agents 19.28 14.79 27 12419 173634 29388447
Disseminated aspergillosis 18.92 14.79 7 12439 414 29561667
Viral uveitis 18.43 14.79 4 12442 31 29562050
Post procedural haemorrhage 18.29 14.79 19 12427 7472 29554609
Systemic mastocytosis 18.20 14.79 5 12441 111 29561970
Cardiac valve vegetation 18.18 14.79 7 12439 462 29561619
Coagulation factor VII level decreased 17.83 14.79 5 12441 120 29561961
Shock haemorrhagic 17.75 14.79 21 12425 9530 29552551
Eyelid oedema 17.55 14.79 15 12431 4621 29557460
Headache 17.45 14.79 29 12417 173978 29388103
Appendicitis perforated 17.08 14.79 10 12436 1693 29560388
Pathogen resistance 17.03 14.79 19 12427 8097 29553984
Drug chemical incompatibility 17.03 14.79 3 12443 6 29562075
Arteritis 16.99 14.79 6 12440 310 29561771
Procedural hypotension 16.87 14.79 8 12438 882 29561199
Blood creatine phosphokinase MB increased 16.79 14.79 10 12436 1747 29560334
Nodal rhythm 16.62 14.79 9 12437 1311 29560770
Product dose omission issue 16.60 14.79 10 12436 96373 29465708
Haemolytic anaemia 16.35 14.79 20 12426 9399 29552682
Laryngeal oedema 16.12 14.79 12 12434 3036 29559045
Cardiac arrest 16.09 14.79 75 12371 85516 29476565
Angioedema 16.03 14.79 39 12407 31876 29530205
Toxic shock syndrome 15.96 14.79 6 12440 371 29561710
Electrocardiogram ST segment elevation 15.93 14.79 14 12432 4478 29557603
Acinetobacter infection 15.82 14.79 8 12438 1014 29561067
Asthenia 15.64 14.79 43 12403 215207 29346874
Prothrombin level decreased 15.56 14.79 8 12438 1050 29561031
Pseudomembranous colitis 15.50 14.79 11 12435 2586 29559495
Arthrofibrosis 15.40 14.79 4 12442 71 29562010
Diarrhoea 15.38 14.79 80 12366 332618 29229463
Disseminated intravascular coagulation 15.33 14.79 29 12417 19951 29542130
Delayed recovery from anaesthesia 15.26 14.79 7 12439 716 29561365
Pruritus 14.88 14.79 92 12354 116757 29445324
Reperfusion injury 14.86 14.79 4 12442 82 29561999

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 687.26 12.61 300 24529 30028 64443875
Anaphylactic reaction 392.08 12.61 273 24556 68391 64405512
Hypotension 194.05 12.61 442 24387 380532 64093371
Hypoprothrombinaemia 179.34 12.61 44 24785 675 64473228
Acute generalised exanthematous pustulosis 165.76 12.61 89 24740 13969 64459934
Kounis syndrome 128.01 12.61 47 24782 2978 64470925
Fear 116.81 12.61 81 24748 20090 64453813
Vitamin K deficiency 107.84 12.61 29 24800 650 64473253
Urticaria 106.68 12.61 198 24631 147119 64326784
Fatigue 106.57 12.61 80 24749 748650 63725253
Arthrodesis 105.88 12.61 37 24792 2030 64471873
Renal injury 103.79 12.61 68 24761 15361 64458542
Anhedonia 98.58 12.61 63 24766 13643 64460260
Bronchospasm 95.92 12.61 74 24755 21608 64452295
Erythema 87.15 12.61 210 24619 186860 64287043
Drug-induced liver injury 81.37 12.61 96 24733 47547 64426356
Unevaluable event 80.11 12.61 98 24731 50391 64423512
Injury 79.80 12.61 103 24726 55889 64418014
Drug reaction with eosinophilia and systemic symptoms 76.11 12.61 99 24730 54118 64419785
Rash 70.20 12.61 355 24474 458194 64015709
Renal failure 69.11 12.61 189 24640 181499 64292404
Blood pressure decreased 67.59 12.61 120 24709 86079 64387824
Type I hypersensitivity 66.96 12.61 31 24798 3543 64470360
Emotional distress 63.83 12.61 74 24755 35964 64437939
Post procedural complication 63.60 12.61 58 24771 21295 64452608
Tachycardia 56.26 12.61 155 24674 149424 64324479
Drug hypersensitivity 53.70 12.61 207 24622 237608 64236295
Anaesthetic complication 53.45 12.61 24 24805 2555 64471348
Cardiac arrest 51.48 12.61 153 24676 153911 64319992
Toxic epidermal necrolysis 50.81 12.61 67 24762 37099 64436804
Hypovitaminosis 49.76 12.61 17 24812 871 64473032
Headache 49.31 12.61 80 24749 529387 63944516
Shock 49.31 12.61 67 24762 38173 64435730
Coagulopathy 49.07 12.61 61 24768 31859 64442044
Clostridium difficile colitis 48.37 12.61 56 24773 27167 64446736
Toxicity to various agents 46.39 12.61 43 24786 363470 64110433
Multiple organ dysfunction syndrome 45.19 12.61 112 24717 101301 64372602
Dizziness 43.90 12.61 61 24768 430102 64043801
Hepatic function abnormal 43.45 12.61 84 24745 64229 64409674
Vascular purpura 41.23 12.61 20 24809 2536 64471367
Death 41.22 12.61 77 24752 482628 63991275
Malaise 40.61 12.61 56 24773 396191 64077712
Renal impairment 40.36 12.61 129 24700 134888 64339015
Post procedural haematoma 40.17 12.61 19 24810 2279 64471624
Linear IgA disease 39.68 12.61 20 24809 2754 64471149
Product dose omission issue 39.27 12.61 13 24816 194734 64279169
Disseminated intravascular coagulation 39.19 12.61 55 24774 32293 64441610
Joint swelling 39.06 12.61 17 24812 215365 64258538
Hyperthermia malignant 38.94 12.61 19 24810 2440 64471463
Pseudomembranous colitis 38.87 12.61 24 24805 4892 64469011
Weight increased 38.44 12.61 17 24812 213331 64260572
Tubulointerstitial nephritis 38.11 12.61 53 24776 30856 64443047
Lymphoid tissue hypoplasia 38.00 12.61 12 24817 479 64473424
Post procedural hypotension 37.35 12.61 8 24821 64 64473839
Vitamin K decreased 37.13 12.61 8 24821 66 64473837
Thymus hypoplasia 37.03 12.61 12 24817 521 64473382
Peripheral swelling 35.63 12.61 18 24811 209135 64264768
Weight decreased 35.03 12.61 35 24794 285704 64188199
Sinusitis 34.65 12.61 7 24822 145921 64327982
Disseminated aspergillosis 34.38 12.61 12 24817 656 64473247
Recurrence of neuromuscular blockade 33.75 12.61 9 24820 195 64473708
Rash maculo-papular 33.71 12.61 63 24766 46963 64426940
Haemolytic anaemia 33.64 12.61 36 24793 16017 64457886
Pain in extremity 32.91 12.61 41 24788 303044 64170859
Ventricular tachycardia 32.55 12.61 52 24777 34213 64439690
Shock haemorrhagic 32.30 12.61 36 24793 16755 64457148
Arthralgia 31.54 12.61 78 24751 442182 64031721
Toxic skin eruption 31.49 12.61 38 24791 19246 64454657
Pseudomonal sepsis 30.47 12.61 21 24808 5151 64468752
Alopecia 30.16 12.61 13 24816 165677 64308226
Post procedural haemorrhage 29.87 12.61 30 24799 12401 64461502
Device related infection 29.81 12.61 47 24782 30579 64443324
Injection site pain 29.43 12.61 4 24825 111404 64362499
Diarrhoea 29.43 12.61 161 24668 722543 63751360
Drug intolerance 29.38 12.61 18 24811 187974 64285929
Angioedema 29.36 12.61 70 24759 61751 64412152
Shoulder arthroplasty 28.74 12.61 16 24813 2693 64471210
Asthenia 28.59 12.61 78 24751 427966 64045937
Arthrofibrosis 28.31 12.61 7 24822 111 64473792
Brain herniation 28.24 12.61 22 24807 6511 64467392
Hepatic enzyme abnormal 28.18 12.61 21 24808 5818 64468085
Procedural hypotension 28.16 12.61 14 24815 1872 64472031
Dysbiosis 27.45 12.61 11 24818 884 64473019
Heparin-induced thrombocytopenia 27.16 12.61 24 24805 8455 64465448
Face oedema 26.92 12.61 40 24789 24721 64449182
Staphylococcal bacteraemia 26.75 12.61 26 24803 10329 64463574
Pyrexia 26.63 12.61 330 24499 558314 63915589
Conjunctival ulcer 26.55 12.61 6 24823 63 64473840
Nasopharyngitis 26.42 12.61 22 24807 196051 64277852
Fall 26.33 12.61 78 24751 416748 64057155
Tarsal tunnel syndrome 25.71 12.61 9 24820 496 64473407
Purpura senile 25.61 12.61 9 24820 502 64473401
Limb operation 25.51 12.61 15 24814 2799 64471104
Pericarditis fungal 25.49 12.61 7 24822 170 64473733
Metabolic acidosis 25.14 12.61 72 24757 70886 64403017
Gastritis fungal 24.90 12.61 7 24822 186 64473717
Tonic clonic movements 24.58 12.61 13 24816 1976 64471927
Laryngeal oedema 24.53 12.61 21 24808 7092 64466811
Drug eruption 24.16 12.61 47 24782 36089 64437814
Acute hepatic failure 23.95 12.61 39 24790 26073 64447830
Adrenal suppression 23.28 12.61 11 24818 1316 64472587
Bradycardia 22.74 12.61 98 24731 118121 64355782
Off label use 22.54 12.61 147 24682 632659 63841244
Insomnia 22.27 12.61 26 24803 197810 64276093
Acinetobacter infection 22.16 12.61 13 24816 2416 64471487
Pruritus 22.12 12.61 200 24629 312200 64161703
Clostridium difficile infection 21.74 12.61 45 24784 36118 64437785
Intrapericardial thrombosis 21.67 12.61 5 24824 58 64473845
Brain oedema 21.65 12.61 34 24795 22041 64451862
Oropharyngeal pain 21.64 12.61 4 24825 88863 64385040
Pyomyositis 21.41 12.61 8 24821 532 64473371
Thrombotic microangiopathy 21.19 12.61 29 24800 16626 64457277
Airway peak pressure increased 21.05 12.61 7 24822 330 64473573
Jaundice cholestatic 20.97 12.61 21 24808 8649 64465254
Post embolisation syndrome 20.74 12.61 5 24824 71 64473832
Meningitis fungal 20.71 12.61 6 24823 178 64473725
Pulseless electrical activity 20.63 12.61 25 24804 12714 64461189
Haemodynamic instability 20.55 12.61 27 24802 14885 64459018
Skin graft 20.40 12.61 9 24820 919 64472984
Manipulation 20.24 12.61 5 24824 79 64473824
Electrocardiogram ST segment elevation 20.22 12.61 19 24810 7240 64466663
Macular oedema 20.19 12.61 16 24813 4851 64469052
Eosinophilia 20.15 12.61 45 24784 38031 64435872
Intentional product use issue 19.86 12.61 6 24823 95358 64378545
Coagulation factor X level decreased 19.52 12.61 5 24824 92 64473811
Kidney transplant rejection 19.35 12.61 21 24808 9490 64464413
Musculoskeletal pain 19.08 12.61 4 24825 81290 64392613
Delayed recovery from anaesthesia 18.92 12.61 10 24819 1518 64472385
Tryptase increased 18.89 12.61 7 24822 455 64473448
Cytomegalovirus viraemia 18.77 12.61 22 24807 10806 64463097
Muscle spasms 18.77 12.61 16 24813 141007 64332896
Blood creatine phosphokinase MB increased 18.72 12.61 12 24817 2609 64471294
Myoclonus 18.43 12.61 34 24795 25084 64448819
Resorption bone increased 18.42 12.61 9 24820 1159 64472744
Intentional product misuse 18.16 12.61 3 24826 72292 64401611
Eyelid oedema 18.13 12.61 23 24806 12256 64461647
Respiratory failure 18.06 12.61 115 24714 161068 64312835
Gastrointestinal disorder 18.05 12.61 6 24823 89703 64384200
Circulatory collapse 18.00 12.61 40 24789 33692 64440211
Balance disorder 17.99 12.61 5 24824 83921 64389982
Gait disturbance 17.93 12.61 24 24805 172131 64301772
Postoperative wound infection 17.92 12.61 21 24808 10315 64463588
Procedural haemorrhage 17.69 12.61 14 24815 4238 64469665
Contusion 17.68 12.61 11 24818 113954 64359949
Spinal cord haematoma 17.66 12.61 6 24823 302 64473601
Premature delivery 17.36 12.61 28 24801 18561 64455342
Fear of death 17.33 12.61 9 24820 1318 64472585
Stress 17.31 12.61 57 24772 60477 64413426
Hypoventilation 17.27 12.61 16 24813 5990 64467913
Delayed graft function 17.12 12.61 12 24817 3024 64470879
Implant site haematoma 16.98 12.61 5 24824 157 64473746
Dyspnoea 16.98 12.61 186 24643 718488 63755415
Diabetes insipidus 16.93 12.61 14 24815 4507 64469396
Factor V inhibition 16.80 12.61 6 24823 351 64473552
Procedural pain 16.78 12.61 25 24804 15483 64458420
Feeling abnormal 16.77 12.61 16 24813 133586 64340317
Hepatitis cholestatic 16.74 12.61 22 24807 12133 64461770
Procedural complication 16.48 12.61 17 24812 7248 64466655
Septic shock 16.29 12.61 82 24747 105355 64368548
Pathogen resistance 16.20 12.61 22 24807 12521 64461382
Infusion related reaction 16.06 12.61 24 24805 164443 64309460
Drug chemical incompatibility 15.97 12.61 4 24825 67 64473836
Mycobacterial peritonitis 15.97 12.61 4 24825 67 64473836
Systemic lupus erythematosus 15.95 12.61 5 24824 77607 64396296
Coagulation factor VII level decreased 15.73 12.61 5 24824 204 64473699
Irregular breathing 15.70 12.61 6 24823 425 64473478
Staphylococcal infection 15.65 12.61 49 24780 50629 64423274
Herpes simplex hepatitis 15.51 12.61 6 24823 439 64473464
Mobility decreased 15.19 12.61 7 24822 85833 64388070
Vestibular disorder 15.16 12.61 10 24819 2283 64471620
Asthma 15.03 12.61 9 24820 95216 64378687
Lower respiratory tract infection 14.86 12.61 9 24820 94605 64379298
Spontaneous haematoma 14.85 12.61 8 24821 1263 64472640
Cardiac valve vegetation 14.75 12.61 7 24822 846 64473057
Encephalopathy 14.74 12.61 53 24776 58766 64415137
Wound infection 14.73 12.61 23 24806 14841 64459062
Catheter site haemorrhage 14.71 12.61 13 24816 4578 64469325
Myalgia 14.68 12.61 24 24805 158593 64315310
Laryngeal dyspnoea 14.60 12.61 5 24824 258 64473645
Disease progression 14.50 12.61 20 24809 141660 64332243
Toxic shock syndrome 14.49 12.61 7 24822 879 64473024
Cataract subcapsular 14.47 12.61 7 24822 882 64473021
Maternal exposure during delivery 14.46 12.61 7 24822 883 64473020
Systemic mastocytosis 14.26 12.61 5 24824 277 64473626
Altered state of consciousness 13.95 12.61 39 24790 37863 64436040
Hypoxia 13.93 12.61 69 24760 88080 64385823
Clostridium test positive 13.89 12.61 12 24817 4103 64469800
Hypersensitivity vasculitis 13.88 12.61 15 24814 6746 64467157
Jaundice acholuric 13.79 12.61 4 24825 119 64473784
Injection site erythema 13.79 12.61 5 24824 70795 64403108
Aspartate aminotransferase increased 13.75 12.61 86 24743 119702 64354201
Propionibacterium infection 13.73 12.61 5 24824 309 64473594
Decorticate posture 13.69 12.61 5 24824 312 64473591
Memory impairment 13.66 12.61 8 24821 85674 64388229
Vertigo 13.65 12.61 3 24826 59008 64414895
Syncope 13.54 12.61 25 24804 157610 64316293
Stupor 13.47 12.61 14 24815 6021 64467882
Arterial angioplasty 13.41 12.61 3 24826 30 64473873
Appendicitis perforated 13.29 12.61 10 24819 2810 64471093
Cellulitis 13.19 12.61 71 24758 93586 64380317
Exposure during pregnancy 13.14 12.61 62 24767 77613 64396290
Serotonin syndrome 13.08 12.61 39 24790 39243 64434660
Platelet dysfunction 13.00 12.61 5 24824 360 64473543
Respiratory distress 12.98 12.61 47 24782 52284 64421619
Necrotising oesophagitis 12.97 12.61 6 24823 684 64473219
Cough 12.97 12.61 66 24763 302082 64171821
Migraine 12.95 12.61 4 24825 62673 64411230
Serratia test positive 12.93 12.61 4 24825 149 64473754
Myocardial infarction 12.79 12.61 28 24801 165793 64308110
Arteriospasm coronary 12.78 12.61 13 24816 5452 64468451
Endotracheal intubation complication 12.76 12.61 6 24823 710 64473193
Renal tubular necrosis 12.69 12.61 27 24802 22083 64451820
Arteritis 12.66 12.61 6 24823 722 64473181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Pneumonia due to Streptococcus indication 34020007
Lower respiratory tract infection indication 50417007
Bacterial pneumonia indication 53084003 DOID:874
Cholangitis indication 82403002 DOID:9446
Infection of bone indication 111253001
Bacterial endocarditis indication 301183007
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Genitourinary Tract Infections indication
Prevention of Perioperative Infection indication
Prevention of Bacterial Endocarditis off-label use
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.22 acidic
pKa2 12.21 acidic
pKa3 1.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019659 VUID
N0000147751 NUI
D00905 KEGG_DRUG
27164-46-1 SECONDARY_CAS_RN
203171 RXNORM
4017460 VANDF
4019659 VANDF
C0007546 UMLSCUI
CHEBI:474053 CHEBI
CHEMBL1435 ChEMBL_ID
CHEMBL1200523 ChEMBL_ID
D002437 MESH_DESCRIPTOR_UI
DB01327 DRUGBANK_ID
10935 IUPHAR_LIGAND_ID
2991 INN_ID
IHS69L0Y4T UNII
33255 PUBCHEM_CID
35509 MMSL
4371 MMSL
948 MMSL
d00007 MMSL
002720 NDDF
004841 NDDF
387470007 SNOMEDCT_US
80972005 SNOMEDCT_US
81088002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9261 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9262 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9262 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9665 INJECTION, POWDER, FOR SOLUTION 20 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9923 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9923 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9924 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9924 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9983 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3103 SOLUTION 1 g INTRAVENOUS NDA 27 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3105 SOLUTION 2 g INTRAVENOUS NDA 27 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3508 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 26 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9833 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 14 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9834 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 10 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9835 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 11 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2585 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3450 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3451 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3452 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-100 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-100 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-101 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-101 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-102 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-102 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-120 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-706 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-707 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections